RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Seelos Therapeutics Stock

Seelos Therapeutics ROA 2024

Seelos Therapeutics ROA

-6.99

Ticker

SEEL

ISIN

US81577F1093

WKN

A2PDK8

In 2024, Seelos Therapeutics's return on assets (ROA) was -6.99, a 116.28% increase from the -3.23 ROA in the previous year.

Seelos Therapeutics Aktienanalyse

What does Seelos Therapeutics do?

Seelos Therapeutics Inc is an emerging company in the biotechnology industry that focuses on the development of novel therapeutics for patients with unmet medical needs. The company was founded in 2016 by Raj Mehra and is headquartered in New York City. Seelos Therapeutics Inc specializes in the development of therapeutics for neurological and psychiatric disorders, with a focus on treating patients with severe, chronic, or life-threatening conditions. The company has developed an innovative business model based on collaboration with various institutions, organizations, and companies. The company is divided into several divisions, including clinical development, product development, technology development, and strategic partnerships. Each division focuses on specific aspects of therapy development and contributes to Seelos' ability to develop innovative and effective therapeutics for its patients. In the clinical development division, Seelos Therapeutics Inc focuses on conducting clinical trials to assess the efficacy and safety of its therapeutics. The company works closely with various academic institutions and clinics to conduct its clinical studies and ensure they adhere to the highest scientific standards. The product development division is responsible for the development of Seelos' actual therapeutics. It encompasses research, development, manufacturing, and quality assurance of the company's products. Seelos emphasizes rigorous quality and safety management to ensure its products meet the highest standards. In the technology development division, Seelos focuses on developing innovative technologies for therapy development. In collaboration with various institutions and companies, the company invests in the development of new technologies to improve its therapeutics and optimize patient care. A crucial aspect of Seelos' business model is collaboration with other companies and institutions. The company has formed strategic partnerships with various institutions and companies in the biotechnology and pharmaceutical fields. This allows Seelos to leverage the expertise and resources of other companies and expedite the development of its therapeutics. Seelos' flagship product is SLS-002, a novel rapid-onset nasal ketamine for the treatment of suicidality in patients with depression and bipolar disorder. SLS-002 has shown promising results in clinical trials and is currently in Phase 2b of clinical development. Seelos is also working on the development of therapeutics for other neurological and psychiatric disorders, such as Huntington's disease, neuropathic pain, and Amyotrophic Lateral Sclerosis (ALS). Overall, Seelos Therapeutics Inc is an emerging company in the biotechnology industry that focuses on the development of novel therapeutics for patients with unmet medical needs. Through its innovative business model and collaboration with other companies and institutions, Seelos aims to expedite the development of its therapeutics and improve the lives of patients with severe, chronic, or life-threatening conditions. Seelos Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Seelos Therapeutics's Return on Assets (ROA)

Seelos Therapeutics's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Seelos Therapeutics's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Seelos Therapeutics's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Seelos Therapeutics’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Seelos Therapeutics stock

What is the Return on Assets (ROA) of Seelos Therapeutics this year?

The Return on Assets (ROA) of Seelos Therapeutics is -6.99 undefined this year.

What was the ROA of Seelos Therapeutics compared to the previous year?

The ROA of Seelos Therapeutics has increased by 116.28% compared to the previous year.

What consequences do high ROA have for investors of Seelos Therapeutics?

A high ROA is advantageous for investors of Seelos Therapeutics, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Seelos Therapeutics?

A low ROA can be unfavorable for investors of Seelos Therapeutics as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Seelos Therapeutics affect the company?

An increase in ROA of Seelos Therapeutics can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Seelos Therapeutics impact the company?

A reduction in the ROA of Seelos Therapeutics can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Seelos Therapeutics?

Some factors that can influence the ROA of Seelos Therapeutics include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Seelos Therapeutics important for investors?

The ROA of Seelos Therapeutics is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Seelos Therapeutics take to improve ROA?

To improve ROA, Seelos Therapeutics can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Seelos Therapeutics pay?

Over the past 12 months, Seelos Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Seelos Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Seelos Therapeutics?

The current dividend yield of Seelos Therapeutics is .

When does Seelos Therapeutics pay dividends?

Seelos Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Seelos Therapeutics?

Seelos Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Seelos Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Seelos Therapeutics located?

Seelos Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Seelos Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Seelos Therapeutics from 10/6/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/6/2024.

When did Seelos Therapeutics pay the last dividend?

The last dividend was paid out on 10/6/2024.

What was the dividend of Seelos Therapeutics in the year 2023?

In the year 2023, Seelos Therapeutics distributed 0 USD as dividends.

In which currency does Seelos Therapeutics pay out the dividend?

The dividends of Seelos Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Seelos Therapeutics

Our stock analysis for Seelos Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Seelos Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.